



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## CTX-2026

Cat. No.:	HY-P99179
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer <sup>[1]</sup> .	
<b>In Vitro</b>	<p>CTX-2026 (1 µg/mL; 12 h) redirects the cytotoxic activity of Vγ9Vδ2 T cells from multiple donors against BTN3A1<sup>+</sup>OVCAR3 cells or primary HGSOc cells<sup>[1]</sup>.</p> <p>CTX-2026 (1 µg/mL; 6 d) shows a rescuing effect on nonablated CD45<sup>+</sup> T cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
<b>In Vivo</b>	<p>CTX-2026 (5 mg/kg; i.p. for 15 days every 3 days once) effects the tumor growth of NY-OVCAR3 tumor mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	NSG mice with NY-OVCAR3 tumors <sup>[1]</sup>
	Dosage:	5 mg/kg
	Administration:	Intraperitoneal injection; 5 mg/kg 3 days for once; for 15 days
	Result:	Effectively delayed malignant progression from nine different donors.

### REFERENCES

[1]. Payne KK, et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020 Aug 21;369(6506):942-949.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA